Evestra Snags DoD Grant For Experimental Breast Cancer Drug Research

By David Holley, Xconomy San Antonio—A small Texas biotech that develops women’s health ...

Promising Treatment for Ebola Virus to be Tested at Texas Biomed

Ricardo Carrion, Jr., Ph.D. During the West African Ebola outbreak that began in 2013, an experimental ...

Local Biotech Company Retools To Improve Care And Capture Larger Market Opportunities
October 14, 2015

By W. Scott Bailey Reporter/Project Coordinator San Antonio Business Journal

Medical device firm iTraumaCare has made some key changes to its initial product, the iTClamp Hemorrhage Control System. The early-stage company, which has its U.S. headquarters in San Antonio, is introducing a new iteration of the device, which includes an improved design allowing for better handling and use.

The iTClamp is designed to control bleeding in seconds and can be used in the scalp, neck, extremities, groin and axilla areas. The device seals the edges of a wound shut to create a temporary hematoma under pressure that mitigates further blood loss until the wound can be surgically repaired.

The retooled iTClamp, manufactured in Grand Rapids, Michigan, has been re-engineered to address control, design and safety features. The improvements were based on user feedback from the field, according to iTraumaCare President and CEO Joe Brennan.

"This could open new doors to organizations that have been waiting for the next-generation version to be released," said Brennan about heightened interest in the improved device. He expects that the rollout of the latest version of the iTClamp will drive up sales and adoption of the product.

The company, created to develop new treatment options for first responders, emergency medical professionals and military medicine experts dealing with traumatic injuries, was established in Canada in 2010. In 2012, I reported that the company had selected San Antonio as the site for its U.S. headquarters.

Within a few months of establishing a presence in the Alamo City, iTraumaCare secured nearly $4 million in Series A funding. Last fall, the company recruited Brennan to help raise more funding and increase commercial adoption of its initial device.

"We have a product that is going to change the way that patients are treated," Brennan told me.

W. Scott Bailey covers health care, tourism, sports business, economic development; he also plans and edits some special reports.


Stay informed. Subscribe to BioMed SA news alerts.